Immutep LAG-3 Therapeutics Corporate Presentation December 2022

Immutep Limited is a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for oncology and autoimmune disease. The presentation highlights compelling clinical data from lead candidate eftilagimod alpha, which demonstrated doubling of overall response rates to anti-PD-1 monotherapy in multiple solid tumours and featured oral presentations at ASCO and SITC conferences in 2022.